// App-Quantinova.ai

: Thrombotic Events with NovoSeven® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs

Researchers

Presenter

  • Madhvi Rajpurkar

Principal Investigators

  • Stacy E. Croteau

  • Lisa N Boggio

  • David L Cooper

Medical Centers

  • Children's Hosp. of MI, Detroit, MI

  • Children's Hospital Boston, Boston, MA

  • Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL

  • Clinical, Medical & Regulatory Affairs, Novo Nordisk, Inc., Plainsboro, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • NiaStase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved